Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Coatings TrendsCoatings Trends
Not Confirmed
Not Confirmed
03-05 September, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Coatings TrendsCoatings Trends
Industry Trade Show
Not Confirmed
03-05 September, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
25 Aug 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/actuate-therapeutics-advances-a-new-era-in-oncology-with-potential-universal-backbone-1064578
06 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/06/3128350/0/en/Actuate-Therapeutics-To-Collaborate-with-Incyte-Corporation-and-the-University-of-Pittsburgh-on-Clinical-Trial-of-Elraglusib-in-Combination-with-Retifanlimab-and-mFOLFIRINOX-in-Pat.html
17 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/17/3117225/0/en/Actuate-Therapeutics-Advances-Clinical-Program-in-Ewing-Sarcoma-After-Positive-Phase-1-Trial-Demonstrates-Complete-and-Partial-Responses-in-Difficult-to-Treat-Pediatric-Sarcomas.html
24 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/24/3104339/0/en/Actuate-Therapeutics-Highlights-Significant-and-Sustained-Survival-Benefit-in-Key-Metastatic-Pancreatic-Cancer-Patient-Populations-in-Phase-2-Elraglusib-Trial.html
20 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/20/3102706/0/en/Actuate-Therapeutics-Reports-Positive-Biomarker-and-Machine-Learning-Data-from-Phase-2-Elraglusib-Trial-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer-at-ASCO.html
16 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/16/3099814/0/en/Actuate-Therapeutics-Announces-Inclusion-in-the-Russell-3000-and-Russell-2000-Indexes.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE